b-cell-depletion-therapy-can-help-refractory-patients-in-remaining-stableThirty six percent of patients suffering from refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without feeling or requiring the need of further standard immunosuppressive agents. This finding was disclosed by a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

It is important to note here that minimizing the number of B-cells in the system by BCDT has been suggested as a potential therapy to SLE patients unresponsive to other treatments.

Co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom, said that results are encouraging and suggest that B-cell depletion therapy is a promising therapeutic option for lupus patients besides reducing the need for continuous immunosuppressive therapy.